{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:41Z","timestamp":1786984301376,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.amjms.2024.12.008","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T02:54:32Z","timestamp":1734576872000},"page":"653-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Changing paradigms in asthma management"],"prefix":"10.1016","volume":"369","author":[{"given":"Charles E.","family":"Grogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlee","family":"Wadsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Gailen D.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjms.2024.12.008_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/ijms25010182","article-title":"Personalized medicine in severe asthma: from biomarkers to biologics","volume":"25","author":"Chen","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"18","key":"10.1016\/j.amjms.2024.12.008_bib0002","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.3390\/jcm12185846","article-title":"Severe asthma and biological therapies: now and the future","volume":"12","author":"Sardon-Prado","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjms.2024.12.008_bib0003","first-page":"45","article-title":"Difficult-to-treat and severe asthma: can real-world studies on effectiveness of biological treatments change the lives of patients?","volume":"15","author":"Pelaia","year":"2024","journal-title":"Pragmat Obs Res"},{"issue":"8","key":"10.1016\/j.amjms.2024.12.008_bib0004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/thx.2009.128504","article-title":"Single maintenance, and reliever therapy (SMART) of asthma: a critical appraisal","volume":"65","author":"Chapman","year":"2010","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.amjms.2024.12.008_bib0005","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clinic Immunol"},{"issue":"8","key":"10.1016\/j.amjms.2024.12.008_bib0006","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.amjmed.2023.05.001","article-title":"An update on monoclonal antibody therapy to treat moderate-to-severe asthma: benefits, choices, and limitations","volume":"136","author":"Elliott","year":"2023","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.amjms.2024.12.008_bib0007","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.amjms.2024.12.008_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.839011","article-title":"Omalizumab and IgE in the control of severe allergic asthma","volume":"13","author":"Gon","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.amjms.2024.12.008_bib0009","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"issue":"7","key":"10.1016\/j.amjms.2024.12.008_bib0010","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"10.1016\/j.amjms.2024.12.008_bib0011","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.amjms.2024.12.008_bib0012","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molimm.2022.03.119","article-title":"Exploring the efficacy and contribution of Dupilumab in asthma management","volume":"146","author":"Alsaffar","year":"2022","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.amjms.2024.12.008_bib0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41577-022-00735-y","article-title":"Role of thymic stromal lymphopoietin in allergy and beyond","volume":"23","author":"Ebina-Shibuya","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.amjms.2024.12.008_bib0014","first-page":"671","article-title":"Dramatic response to tezepelumab as an initial biologic agent for refractory asthma associated with type 2 and non-type 2 traits","volume":"77","author":"Minami","year":"2023","journal-title":"Acta Med Okayama"},{"issue":"1","key":"10.1016\/j.amjms.2024.12.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00528-2020","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Hinks","year":"2021","journal-title":"Eur Respir J"},{"issue":"10379","key":"10.1016\/j.amjms.2024.12.008_bib0016","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2024.12.008_bib0017","first-page":"165","article-title":"CRTH2 antagonists in asthma: current perspectives","volume":"9","author":"Singh","year":"2017","journal-title":"Clinic Pharmacol"},{"issue":"5","key":"10.1016\/j.amjms.2024.12.008_bib0018","first-page":"e24641","article-title":"Efficacy and safety of fevipiprant in asthma: a review and meta-analysis","volume":"14","author":"Jahangir","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.amjms.2024.12.008_bib0019","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.amjms.2024.12.008_bib0020","series-title":"Global Strategy for Asthma Management and Prevention","article-title":"Global initiative for Asthma","year":"2023"},{"issue":"1","key":"10.1016\/j.amjms.2024.12.008_bib0021","first-page":"S31","article-title":"A practical guide to implementing SMART in asthma management","volume":"10","author":"Reddel","year":"2022","journal-title":"J Allergy Clinic Immunol"},{"issue":"20","key":"10.1016\/j.amjms.2024.12.008_bib0022","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","article-title":"Inhaled combined budesonide\u2013formoterol as needed in mild asthma","volume":"378","author":"O'Byrne","year":"2018","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.amjms.2024.12.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0615","article-title":"Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis","volume":"5","author":"Beasley","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.amjms.2024.12.008_bib0024","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.anai.2022.07.024","article-title":"SMART in treatment of asthma exacerbations","volume":"129","author":"Imam","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.amjms.2024.12.008_bib0025","series-title":"AstraZeneca Expands Savings Programs, Caps Inhaler Costs at $35 per Month","year":"2023"},{"issue":"11","key":"10.1016\/j.amjms.2024.12.008_bib0026","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/life11111215","article-title":"Effectiveness of telemonitoring for respiratory and systemic symptoms of asthma and COPD: a narrative review","volume":"11","author":"Metting","year":"2021","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.amjms.2024.12.008_bib0027","first-page":"510","article-title":"The effectiveness and value of biologic therapies for the treatment of uncontrolled asthma","volume":"25","author":"Tice","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.amjms.2024.12.008_bib0028","series-title":"Biologic Therapies for Treatment of Asthma Associated With Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Evidence Report Prepared For","year":"2018"},{"issue":"2","key":"10.1016\/j.amjms.2024.12.008_bib0029","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1378\/chest.117.2.542","article-title":"Inhaled corticosteroids for asthma therapy","volume":"117","author":"Cochrane","year":"2000","journal-title":"Chest"},{"issue":"163","key":"10.1016\/j.amjms.2024.12.008_bib0030","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0176-2021","article-title":"Current unmet needs and potential solutions to uncontrolled asthma","volume":"31","author":"Busse","year":"2022","journal-title":"Eur Respir Rev"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924015623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924015623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:54:50Z","timestamp":1748858090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924015623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0002962924015623"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.12.008","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changing paradigms in asthma management","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}